TG Therapeutics Inc [NASDAQ: TGTX] price surged by 2.55 percent to reach at $0.34. The one-year TGTX stock forecast points to a potential upside of 51.71. The average equity rating for TGTX stock is currently 1.62, trading closer to a bullish pattern in the stock
TG Therapeutics Inc [NASDAQ: TGTX] price plunged by -0.50 percent to reach at -$0.07. The one-year TGTX stock forecast points to a potential upside of 50.83. The average equity rating for TGTX stock is currently 1.62, trading closer to a bullish pattern in the stock
TG Therapeutics Inc [NASDAQ: TGTX] slipped around -0.18 points on Wednesday, while shares priced at $13.82 at the close of the session, down -1.29%. Compared to the average trading volume of 3.57M shares, TGTX reached a trading volume of 3060830 in the most recent trading
TG Therapeutics Inc [NASDAQ: TGTX] stock went on a downward path that fall over -2.35% on Thursday, amounting to a one-week price decrease of less than -14.67%. The company report on March 8, 2024 at 7:30 AM that TG Therapeutics Announces Schedule of Data Presentations
TG Therapeutics Inc [NASDAQ: TGTX] traded at a low on Thursday, posting a -1.26 loss after which it closed the day’ session at $18.00. The company report on March 1, 2024 at 7:30 AM that TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple
TG Therapeutics Inc [NASDAQ: TGTX] traded at a high on Tuesday, posting a 4.12 gain after which it closed the day’ session at $13.91. The company report on February 27, 2024 at 7:30 AM that TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy).
TG Therapeutics Inc [NASDAQ: TGTX] traded at a high on Thursday, posting a 3.23 gain after which it closed the day’ session at $13.44. The company report on February 20, 2024 at 7:30 AM that TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab)
TG Therapeutics Inc [NASDAQ: TGTX] loss -8.23% or -1.25 points to close at $13.93 with a heavy trading volume of 4861268 shares. The company report on January 10, 2024 at 7:00 AM that TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue
TG Therapeutics Inc [NASDAQ: TGTX] closed the trading session at $15.31. The company report on January 10, 2024 at 7:00 AM that TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones. Preliminary U.S. BRIUMVI fourth quarter and full
TG Therapeutics Inc [NASDAQ: TGTX] surged by $0.07 during the normal trading session on while it closed the day at $16.24. The company report on January 10, 2024 at 7:00 AM that TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and
© 2024, Powered by Smart TechOne
